Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy

Drug Category : Array
Conference Category : Array
Lead Author : Mato A, et al.
Published Date : 02/12/2020
Download Link : https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020007376/474377/Phase-2-Study-of-the-Safety-and-Efficacy-of?redirectedFrom=fulltext
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top